We are live on
!
Find out more
FCM
Farallon Capital Management Portfolio holdings
AUM
$17.5B
1-Year Est. Return
50.95%
This Fund
S&P 500
This Quarter
Est. Return
+7.53%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$20B
AUM Growth
-$1.4B
(-6.6%)
Cap. Flow
-$2.71B
Cap. Flow
% of AUM
-13.53%
Top 10 Holdings %
Top 10 Hldgs %
37.39%
Holding
342
New
43
Increased
66
Reduced
43
Closed
42
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Adobe
ADBE
|
+$235M |
| 2 |
Howmet Aerospace
HWM
|
+$189M |
| 3 |
Full Truck Alliance
YMM
|
+$174M |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$140M |
| 5 |
AbbVie
ABBV
|
+$133M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
T-Mobile US
TMUS
|
+$588M |
| 2 |
XLRN
Acceleron Pharma
XLRN
|
+$373M |
| 3 |
NUAN
Nuance Communications, Inc.
NUAN
|
+$327M |
| 4 |
Willis Towers Watson
WTW
|
+$319M |
| 5 |
KSU
Kansas City Southern
KSU
|
+$319M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.82% |
| 2 | Industrials | 13.15% |
| 3 | Financials | 12.22% |
| 4 | Communication Services | 10.32% |
| 5 | Technology | 10.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Sarepta Therapeutics
SRPT
$1.77B
| $75.6M | 0.38% |
839,009
+677,009
| +418% | +$57.9M |
|
|
KRTX
52
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $72M | 0.36% |
550,000
-150,000
| -21% | -$19.4M |
|
|
CHNG
53
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $70M | 0.35% |
3,273,600
+535,000
| +20% | +$11.2M |
|
54
United Therapeutics
UTHR
$23.1B
| $69.3M | 0.35% |
+320,760
| New | +$63M |
|
55
Revolution Medicines
RVMD
$44B
| $69.2M | 0.35% |
2,750,000
| – | – |
|
56
Protagonist Therapeutics
PTGX
$9.44B
| $65.6M | 0.33% |
1,917,134
-474,866
| -20% | -$15M |
|
57
Bruker
BRKR
$8.14B
| $62.5M | 0.31% |
+745,266
| New | +$59.7M |
|
|
AMRS
58
DELISTED
Amyris Inc.
AMRS
| $58.8M | 0.29% |
10,859,811
-859,114
| -7% | -$8.02M |
|
|
IMGO
59
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
| $58.6M | 0.29% |
2,471,313
-200,000
| -7% | -$4.63M |
|
|
ATTO
60
DELISTED
Atento S.A.
ATTO
| $56.9M | 0.28% |
2,230,357
| – | – |
|
61
Jazz Pharmaceuticals
JAZZ
$16.7B
| $54.9M | 0.27% |
431,021
-143,886
| -25% | -$18.9M |
|
|
ARNA
62
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $48.5M | 0.24% |
522,000
-134,548
| -20% | -$8.86M |
|
|
BRMK
63
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
| $45.7M | 0.23% |
4,850,000
-106,174
| -2% | -$1.05M |
|
64
Qiagen
QGEN
$8.72B
| $45.2M | 0.23% |
767,708
-622,213
| -45% | -$35.7M |
|
|
ZGNX
65
DELISTED
Zogenix, Inc.
ZGNX
| $45M | 0.22% |
2,766,935
| – | – |
|
|
ZEN
66
DELISTED
ZENDESK INC
ZEN
| $44.8M | 0.22% |
+430,000
| New | +$46.1M |
|
67
Caribou Biosciences
CRBU
$164M
| $44.7M | 0.22% |
2,963,448
| – | – |
|
68
Fate Therapeutics
FATE
$326M
| $44.3M | 0.22% |
757,425
-1,553,973
| -67% | -$88.1M |
|
69
Pacific Biosciences
PACB
$370M
| $41.9M | 0.21% |
2,045,488
+53,238
| +3% | +$1.28M |
|
70
Agios Pharmaceuticals
AGIO
$1.93B
| $41.3M | 0.21% |
1,256,578
+437,811
| +53% | +$17.6M |
|
71
Repligen
RGEN
$9.25B
| $36.1M | 0.18% |
136,245
+45,175
| +50% | +$12.2M |
|
72
Biogen
BIIB
$30.7B
| $35.4M | 0.18% |
147,709
-23,150
| -14% | -$5.95M |
|
|
CCXI
73
DELISTED
ChemoCentryx, Inc.
CCXI
| $34.1M | 0.17% |
935,463
+549,463
| +142% | +$19.3M |
|
|
GATE
74
DELISTED
Marblegate Acquisition Corp. Class A Common Stock
GATE
| $29M | 0.14% |
+2,970,000
| New | +$29.1M |
|
|
MNTV
75
DELISTED
Momentive Global Inc. Common Stock
MNTV
| $28.4M | 0.14% |
+1,342,000
| New | +$29.5M |
|
Similar funds
BBA
MCM
LA
CM
ASRS
PP
VMPIC
HNB
Farallon Capital Management's Q4 2021 Portfolio in Review
As of Q4 2021, Farallon Capital Management held 342 positions worth $20B, down 6.6% from $21.4B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Farallon Capital Management withdrew a net $2.71B in Q4 2021, closing 42 positions and reducing 43 holdings. Its most notable exit was T-Mobile US, an estimated $588M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 29% a quarter earlier, followed by Industrials and Financials.
Against the trend, Farallon Capital Management opened a new position in Adobe worth $213M.
- Farallon Capital Management's largest Q4 2021 buy was Adobe: 376,000 shares worth $213M.
- Farallon Capital Management added most to Howmet Aerospace in Q4 2021, an estimated $189M increase.
- Farallon Capital Management's biggest Q4 2021 reduction was Nuance Communications, Inc., cutting an estimated $327M.
- Farallon Capital Management fully exited T-Mobile US in Q4 2021, selling an estimated $588M.
- Farallon Capital Management's ten largest holdings make up 37% of its $20B portfolio in Q4 2021.
- Farallon Capital Management opened 43 new positions and closed 42 in Q4 2021.
- Farallon Capital Management's portfolio value fell 6.6% quarter-over-quarter to $20B.
Based on Farallon Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.